Depression Screening Market 2018; Comprehensive Analysis by Development Strategy, Future Prospects and Market Growth Prediction by 2023

Market research future published a Cooked research report on Depression Screening Market. The Depression Screening Market is Comprehensive Analysis by Development Strategy, Future Prospects and Market Growth Prediction by 2023.

Depression Screening Market Market Highlights:

Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness. The global depression screening/mental health market has been evaluated as a moderately growing market and it is expected to continue growing in the near future.

Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/3806.

Increasing cases of patients with various mental disorders, changing and stressful lifestyle are driving the growth for the market. Moreover, rising funding for R&D and clinical trials are also driving the growth for the market. Major players of this industry are funding R&D to derive effective solutions for mental health. Major players of this market are holding majority of market share while due to high investment cost, medium and small companies mainly focusing only on manufacturing of drugs rather than R&D. For instance, companies like Eli Lilly and Company, Pfizer Inc., Allergan and some other are spending a rather large amount on R&D for market growth.

The global depression screening market is expected to grow at a CAGR of 6.20% during the forecast period 2017-2023.

Depression Screening Market Key Players:

Some of the key players in this market are Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan),  Pfizer Inc. (US), and others.

Depression Screening Market Market Scenario:      

Depression and mental health are the leading cause of disability and ill health across the globe. Depression affects an estimated one in 15 adults every year and also affects one in six people will experience depression at some time in their life. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration

Increasing prevalence of various mental disorder is one of the major driver for the market growth. Furthermore, rising funding for R&D and clinical trials are also supporting the growth of the market. The global depression screening market is expected to grow at a CAGR of 6.20% during the forecast period 2017-2023.

Depression Screening Market Regional Analysis:        

The global depression screening market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

Americas is known to be the largest market. Many top global pharmaceutical companies have their base in this region leading the innovation and new solution development. These companies like Eli Lilly and Company, Pfizer Inc. and some other are spending a rather large amount on R&D for market growth. Middle Eastern countries are dominating in Middle East and Africa market it is mostly due to developed healthcare infrastructure, government support, increasing awareness and rising middle class population. However some factor are prohibiting the market growth such as low awareness of the disorders, reluctance to adopt new therapies, and limited availability of healthcare facilities and products etc.

Get Unexpected Discount @ https://www.marketresearchfuture.com/check-discount/3806 .

Depression Screening Market Segmentation:

The global depression screening market is segmented on the basis of disease type, diagnosis, treatment, and end user.

On the basis of the disease type, it is further segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and other mental and behavioral & disorders.

On the basis of the treatment, the market is segmented into medication (anti-anxiety medications, antidepressants, antipsychotic medications, stimulants, anti-seizures medications and others), brain-stimulation treatments (Vagus Nerve Stimulation (VNS), repetitive Transcranial Magnetic Stimulation (rTMS), Magnetic Seizure Therapy (MST), and Deep Brain Stimulation (DBS)), substance abuse treatment and others.

Depression Screening Market Key Findings:

On the basis of disease type, anxiety is the largest segment and continue to grow with the rate of 5.14% during the forecast period. While depression is the fastest growing segment and is projected to grow at a CAGR of 6.63% from 2016-2023.

On the basis of diagnosis, psychological test is the most widely used diagnostic test in depression screening protocol and is expected to reach USD 1,647.6 million in the year 2023 from USD 1,059.6 million in 2016

On the basis of treatment, medications is the fastest growing market, which is expected to reach USD 1,949.2 million by 2023.

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/3806 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028                  

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@Marketresearchfuture.com

This release was published on openPR.